Our History

Founded in 2019 with a group of community leaders with a long history of serving the rare disease community in different capacities. The group saw the need for global cooperation between the East and the West as a driver of new therapies of the 21st century. Orphan Drugs are largely funded by and developed in the Western world by engaging only 10% of the world’s population. Once approved by the FDA, these treatments are sought by patients globally who may not be able to access or benefit from the drugs designed without being tested on diverse patients representative of the World’s population. 

We saw the need for building collaborative bridges of hope between the Eastern and Western worlds to accelerate discovery and development of novel diagnostics and therapeutics for the global rare disease community.